Abatacept
Term · Oncology and biomedicine · MLC-T-ONC-009571
A soluble fusion protein consisting of the extracellular domain of human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) linked to a modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1) with immunosuppressive activity. Abatacept binds CD80 and CD86 on antigen presenting cells (APCs), blocking interaction with CD28 on T lymphocytes, which initiates a co-stimulatory signal required for full activation of T lymphocytes.
| Identifier | MLC-T-ONC-009571 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | CTL A4-Ig B7 Inhibitor; CTLA4-Ig; cytotoxic T lymphocyte-associated antigen-4 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-009571",
"term": "Abatacept",
"field": "Oncology and biomedicine",
"definition": "A soluble fusion protein consisting of the extracellular domain of human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) linked to a modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1) with immunosuppressive activity. Abatacept binds CD80 and CD86 on antigen presenting cells (APCs), blocking interaction with CD28 on T lymphocytes, which initiates a co-stimulatory signal required for full activation of T lymphocytes.",
"synonyms": [
"CTL A4-Ig B7 Inhibitor",
"CTLA4-Ig",
"cytotoxic T lymphocyte-associated antigen-4"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/abatacept/"
}
Record 152 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.